

Data-Driven Medicine in the COVID-19 Era

Christopher A. Longhurst, MD, MS, FACMI CIO and Associate CMO, UC San Diego Health Clinical Professor of Medicine and Pediatrics @calonghurst

UC San Diego Health

Introduction

December 2019

ORIGINAL ARTICLE BRIEF REPORT

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu, Ph.D., Dingyu Zhang, M.D., Wenling Wang, Ph.D., Xingwang Li, M.D., Bo Yang, M.S., Jingdong Song, Ph.D., Xiang Zhao, Ph.D., Baoying Huang, Ph.D., Weifeng Shi, Ph.D., Roujian Lu, M.D., Peihua Niu, Ph.D., Faxian Zhan, Ph.D., <u>et al.</u>, for the China Novel Coronavirus Investigating and Research Team

March 11, 2020

Coronavirus disease 2019 (COVID-19) Situation Report – 51

March 13, 2020

PROCLAMETI DRI

Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak

* * *

World Health Organization

March 24, 2020

Journal of the American Medical Informatics Association, 0(0), 2020, 1–7 doi: 10.1093/jamia/ocaa037 Research and Applications



OXFORD

Research and Applications

Rapid response to COVID-19: health informatics support for outbreak management in an academic health system

J. Jeffery Reeves (1)¹, Hannah M. Hollandsworth¹, Francesca J. Torriani², Randy Taplitz², Shira Abeles², Ming Tai-Seale³, Marlene Millen⁴, Brian J. Clay⁴ and Christopher A. Longhurst (3)⁴

¹Department of Surgery, University of California, La Jolla, San Diego, California, USA, ²Department of Medicine, Division of Infectious Disease and Global Public Health, University of California, San Diego, California, ³Department of Family Medicine and Public Health, University of California, La Jolla, San Diego, California, USA, ⁴Department of Medicine, Division of Biomedical Informatics, University of California, La Jolla, San Diego, California, USA

*Corresponding Author: James Jeffery Reeves, MD, University of California, 9300 Campus Point Drive, MC7400, La Jolla, San Diego, CA 92037-7400 USA (jreeves@health.ucsd.edu)

Received 18 March 2020; Editorial Decision 18 March 2020; Accepted 19 March 2020

Introduction

- Faced new cases of COVID-19
- Need for rapid build of informatics infrastructure
- >95% of US health systems have an EHR
- All phases of care interface with EHR
- Opportunity to leverage technology to enhance patient care

Methodology

Setting: University of California, San Diego Health

- Regional academic medical center
- 2 acute care hospitals, 2 EDs, several urgent care centers
- Full complement of ambulatory services
- Utilizes Epic (Verona, WI)
- Hosts UCI, UCR, Student Health and 300+ affiliate physicians



Methodology

- Local Situation:
 - San Diego County served as quarantine site for Chinese expatriates and cruise ship passengers
 - Experienced early community spread
- Incident Command Center established on February 5, 2020



Incident Command Center

- "Designed to enable effective and efficient incident management by integrating a combination of facilities, equipment, personnel, procedures, and communications."
- Our structure includes:
 - Alternating commanding operator
 - Physician leaders
 - Administration
 - Facility manager
 - Information services
- Identified technological and electronic health record-related needs to support the crisis

Incident Command System Resources. Federal Emergency Management Agency. US Department of Homeland Security. https://www.fema.gov/incident-command-system-resources

Health IT Needs Identified

Electronic Health Record Tools for Managing a Pandemic
Screening Protocols
Triage of Patient Phone Calls
Required Registration/Check-In Screening Questions for All Patients
System Level EHR-Templates
Updated with Current Infection Control Specialist and Command Center Information
Inpatient, Emergency Department and Ambulatory Order Panels
Decision support for testing protocol
Embedded modifiable required isolation orders
Detailed personal protective equipment needs for providers
Detailed instructions for proper specimen collection
Reporting and Analytics
COVID-19 Operational Dashboard
Tracking of COVID-19 and Personal under Investigation (PUIO) in EHR embedded database
Communication Channels
EHR-integrated secure messaging
Artificial Intelligence
Real-time algorithm to assist in diagnostic imaging
Patient Facing Technology
Telemedicine – Video Visits for Outpatient Clinic Encounters Smart tablets in patient rooms w/ video capabilities

Travel and Screening Questions



Figure 1. Travel and symptom screening. The above screenshot demonstrates the required screening, as viewed by front desk staff, that was added to the registration/check-in process for all patients.

EHR Based Templated Phrases

.UCSDCOVID19AMBULATORY

Ambulatory COVID-19 Evaluation (last updated 4/9/2020)

GUIDANCE EVOLVES AS OUR TESTING CAPACITY EVOLVES AND THE COVID-19 OUTBREAK EVOLVES. THANK YOU FOR WORKING WITH US AND UNDERSTANDING GUIDANCE IS CHANGING QUICKLY.

Check-in

- All patients with symptoms of an acute respiratory viral infection and personnel evaluating should be given a surgical mask as soon as they enter the clinic (give at front desk or front door). Make sure the patient is instructed to wear over their nose and mouth and asked to use an alcohol hand rub on their hands.
- Patients who have respiratory symptoms (fever, cough, shortness of breath) should be placed immediately in a private room, alert physician. Any patient companion should also wear a surgical mask. All staff interacting face to face with patient (i.e. vitals, exam, testing, etc) should be instructed to wear a surgical mask, eye protection, gown, and gloves when interacting with the patient.

Evaluation of patient:

Does patient have a fever, a new cough or shortness of breath (SOB) {Yes / No:63} Other symptoms seen in COVID 19 patients include NEW chest tightness, anosmia

EHR Based Templated Phrases

Smart phrase	Setting of use	Description of content					
.UCSDCOVID19TRIAGE	Phone or in person patient triage	Updated travel and symptom screening, testing criteria, and clear guidance on best setting and location of patient care					
.UCSDCOVID19PATIENTCONCERNS	Phone or in person patient en- counter	Detailed information on frequently asked questions concerning COVID-19					
.UCSDCOVID19HOMEISOLATION	When instructing patients on home isolation	Isolation information for patients, including the discontinuation of home isolation					
.UCSDCOVID19AMBULATORY	Ambulatory screening or testing	Clinical decision support on testing criteria, recommended addi- tional work-up, admission criteria/protocol, and discharge infor- mation					
.UCSDCOVID19URGENTCARE	Urgent Care/ED screening or testing	Clinical decision support on testing criteria, recommended addi- tional work-up, admission criteria/protocol, and discharge infor- mation					
.UCSDCOVID19VISITORSCREENING	Clinics or inpatient units	Standard documentation of any screening of patient visitors for symptoms of infection					
UCSD COVID-19 WORK EXCUSE	Work excuse letter	Templated excuse letter for providers to recommend working from home					

Table 2. Modifiable templates available in the electronic health record

Order Panels

COVID-19 Coronavirus Diagnostic Testing and Isolation Orders	✓ Accept
This COVID-19 order is intended to be used in patients with symptoms suggestive of no coronavirus infection.	vel
It includes contact and droplet isolation orders, and the patient will be labeled as "Rule COVID-19" in Epic.	Out
Do <u>NOT</u> use this order option for pre-operative or pre-procedural screening of asymptomatic patients.	
COVID-19 Coronavirus Diagnostic Testing and Isolation Orders	
Given the increased capacity for testing, an ID approval code is no longer required to obtain this test.	
Note: If the patient is in the ICU, or is receiving aerosol-generating procedures, airborne isolation is required in addition to the standard contact and droplet isolation. Select the airborne isolation order below if that is the case. The critical care attending determine whether an airborne isolation room is clinically indicated.	will
To conduct testing for COVID-19, only a single nasopharyngeal specimen needs to be obtained.	
The lab is <u>no longer</u> automatically running a respiratory pathogen nucleic acid (RPNA) panel when a COVID-19 test is ordered. also you wish to order an RPNA, select the RPNA order as well.	If
COVID-19 Coronavirus Detection Assay at UCSD Labs	
Routine, ONCE, First occurrence today at 1015	
Upper Respiratory Pathogen Nucleic Acid Detection Test This RPNA test is being ordered in conjunction with a COVID-19 test. Both tests can be run by the laboratory with only a single nasopharyngeal swab specimen.	~
O Next Required	✓ Accept

© 2020 Epic Systems Corporation. Used with permission.

Daily COVID-19 Dashboard



SHEARINGS for a line works of the area deletion. Note that a works need to the Dust to cost date of and,"

(a) Sept there is an an experimental five instance in proceeding to the second s second se

For Access Research, placet scientif an instalation from Research

Ward Halberth person and contrast to default/Chalolog, how, strictly contrast and Silburning, MOD Service, Deling

East Married, community and page direction for he calculated by Dyna parallel and D. Braw Dire

Daily COVID-19 Dashboard



III Non-Investin Gare Rectify Point of ... III Transfer from a Hospital 3D (DVP.

Daily COVID-19 Dashboard



COVID-19 Registry

	Active Covid Reg	gistry Patients			Ethnick	ty				Race			
	Covid	PUI	Negative	Ethnicity	Covid	PUL	Regative.	Pt Latio.	Race	Cavid	PUL	Megative	Pt Rented
	363	287	8,239	Non-Hispatic	191	123	5,642	04	White	134	137	4,341	
				Hesponic	10	38	1,527		Other Bace or Mixed B.	120	16	2.679	
luster Visu	alization			Hard Street Stations	10		543		Asian	27	-40	719	
March 2	9.2020		• >	Calatasian	1	.6	120		Nut	49	1.1	540	
Show Hist	hanv			Hopponic/Latino	2		- 24	1	Black or African Ameri.	19	0	-494	
Contrast Present				Multi-Reckel	2.1	1	.34		Untroisen (Patient can.	24	59	-1012	
-				Asian/Pacific Islander		14	- 22		Nativa Hawailan or Ot.	2	4	-44	
			817	American Millery Eski.		1	10		American Indian or Ala.	1	1	- 30	
	Geomer: Datient	e hu Datient 7in		A.o.	as Group	e .		Covid	Registr		Sav		
Nicos -	12127			Age 55-64 (2.40) Age 65-74 (461)									
and market for a	ACCEST ACCEST		2	Aga 55.64 Aga 65.74 Aga 75.68 Aga 75.68 Aga 75.6 Aga 75.6	*N	ote: Pi	atients	Comort	u bidities e multiple comorbi	in pi		ja.	M 9
and and and and and and and and and and	ACCESS AC	NAME AND A	2	Aga 55.64 Tel Aga 65.74 Tel Aga 75.68 Tel Aga 10.1	- rs	a ote: Pi	atients	Comort may hav	u bidities e multiple comorbi	in 12	2	14	44 54
the start of the s	90000 90008 900000000	NOTE AND	2	200 22 4 20 1 2010 200 22 4 20 7 2 4 20 1 2 200 22 4 20 4 2 201	-N	ate: Pi	atients Covid	Comort may hav	bidities e multiple comorbi Pui	in Di idities	21.00 20 0 Pt 6	ja.	M Seglat
and and and and and and and and and and	60000 600000 6000000 600000 600000000	NONE AND A	275	Age 52-64 1441 Age 65-74 4421 Age 75-64 11 Age 75-64 11 Bit D	*N	ate: Pi	atients Covid III SH	Cornort may hav	bidities e multiple comorbi pus isi 21	in 12 idities Sepatio 1,00	21.00 27 0 Pt 8	ja.	Al 5 m Regist
and market market for the o	ACCOR STOLES		225	Age 52-c.4 (12.441) Age 65-74 (12.1 Age 75-64 (12.1 Age 15-4 (12.1 Age 15-4 (12.1)) (10.1) (1	*N	ate: Pi	atients Covid III. SB III.	Comort may hav	bidities e multiple comorbi Pui In 21 In	in 14 idities Negativ 1,00 3,000	23 28 • Pt 5	ja.	Al 5
and a second sec	ACCOLOR OF STATES		2 June 1	Age S2-64 1441 Age 65-74 1441 Age 75-68 144 Age 15-68 144 (March 1 (March 1 Hypertansion Production Disbotion	- ×	= ote: Pi	atients Covid III III III III III	Comort may hav	bidities e multiple comorbi PW 14 21 18 18 15	in 15 idities Septio 1,00 1,00 1,00 2,00 2,00 2,00 2,00 2,00	28 • Pts 1 2 0 0	38.	Al 5
and and and and and and and and and and	4000 5000 4000 5000 4000 5000 5000 5000 50000 5		2 July	Cosetty Hypertansion Proteins Agentics State Cosetty Hypertansion Protestors Hay	- 74	ate: Pi	atients Covid III SH III SH III SH III SH	Cornort may hav	bidities e multiple comorbi Pu Id Id Id Id Id Id Id Id Id Id Id Id Id	in 12 idities Negatio 1,00 23 22	28 • Pt 8 1 2 0 0 6	ja.	M Seglet
and market marke	Salado Salado (SALADO Salado (SALADO) Salado (SALADO) Salado (SALADO) Salado (SALADO) Salado		Z	Age 52-64 CLASS Age 65-74 CLASS Age 75-66 Frances Age 75-68 Frances Age 75-68 Frances (Disectly Hypertansion Productors Disabotos HIV Actives	- 75	= ote: Pi	atients Covid III III III III III III III III III I	Cornort may hav	bidities e multiple comorbi Pur M 21 25 25 25 25 25 25 25 25 25 25 25 25 25	00 30 dities Negelie 1,05 0,0 2,0 0,0 0,0 0,0 0,0 0,0 0,0	• Pt #	ja.	m Register
an man mark mark mark mark	9000 90000 9000 9000 9000 9000 9000 9000 9000 9000 9000 9000		Anna C	Age 52-64 1441 Age 65-74 1441 Age 75-64 114 Age 75-64 114 Bill 104 Bill 104 Disestly Hypertansion Produktes Disbotei HW Adlens Tribaco	- 24 - 7N	ate: Pr	44 atients Govid 10 30 30 30 30 30 30 30 30 30 30 30 30 30	Comort may hav	bidities e multiple comorbi Pus Id Id Id Id Id Id Id Id Id Id Id Id Id	01 10 01 10 Idities Negatie 1,02 0,0 7,0 2,0 0,0 7,0 2,0 0,0 7,0 2,0 0,0 7,0 2,0 0,0 7,0 0,0 1,0 1,0 1,0 1,0 1,0 1,0 1	• Pt #	ja.	M Seglet
	ALLEY		eres (Age 52-64 Control of the second secon		ate: Pi	atients Covid III III III III III III III III III I	Comort may hav	bidities e multiple comorbi Pui In In In In In In In In In In In In In	in 18 idities Negetia 1,00 7,3 7,3 7,3 7,5 7,5 7,5 7,5 7,5 7,5 7,5 7,5 7,5 7,5	211 211 211 211 211 211 211 211 211 211	ja.	Al 5
	Samo Samo			Cheerity Hypertansion Proteins Mage 12-10 (10) (10) (10) (10) (10) (10) (10) (1	- 74	in ote: Pi	44 atients Covid 10 30 31 30 31 30 31 30 31 31 31 33 35 35 35 35 35 35 35 35 35 35 35 35	Cornort may hav	bidities e multiple comorbi M M 21 18 18 15 15 11 11 11 11 11 11 11 11 11 11 11	in 15 idities Neption 1,00 23 60 23 60 23 60 23 60 23 60 23 60 23 60 23 23 60 23 23 60 23 24 25 60 25 25 26 26 26 26 26 26 26 26 26 26 26 26 26	9134 24 8 Pt R 1 2 0 0 0 6 6 4 4 8 3 2	ja.	M 3
	A STATUS A STAT			Cheerity Hypertansion Produktion Maritine Maritine Maritine Cheerity Hypertansion Productors Database HW Actives Tableco Scheme Vescular Disse CKD Stryles	- 75	= ote: Pi	40 atients Covid 10 10 10 10 10 10 10 10 10 10 10 10 10	Comort may hav	bidities e multiple comorbi Pur Bid 21 15 15 15 15 15 15 15 15 15 15 15 15 15	00 30 dities Negelie 1,05 00 73 60 60 60 60 60 60 60 60 60 60	21 00 0 0 0 0 0 0 0 0 0 0 0 0	ja.	M Segut
	1000 1000 10000 10000 10000 10000 100000 100000 10000 10000 10000 10000 10000 10000 10000 1000	REAL REAL REAL REAL REAL REAL REAL REAL	A sum	Age 52-64 Carrier Carrier Age 52-64 Carrier Carrier Age 72-64 Carrier Age 72-64 Carrier Age 72-64 Carrier Age 72-64 Carrier Age 72-64 Carrier Carrier Carrier Stockers Have Carrier Stockers Have Carrier Stockers	- 75 - 7N	ote: Pi	40 atients 00vid 10 10 10 10 10 10 10 10 10 10 10 10 10	Cornort may hav	bidities e multiple comorbi Pus M 21 10 15 15 10 11 11 10 11 11 11 11 11 11 11 11 11	01 10 01 10 01 00 00 00 00 00 00 00 00	1141 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	38.	M 5
	ALCOLOGICAL ACCOLOGICAL ACCOLO		eres (Age 52-64 Carrier Carrier Cores (1) Age 52-64 Carrier	- 21	ate: Pr	44 atients 004 01 03 04 03 04 04 05 05 04 05 05 05 05 05 05 05 05 05 05 05 05 05	Comort may hav	bidities e multiple comorbi Pui H 21, 13, 15, 14, 24, 15, 14, 24, 14, 14, 14, 14, 14, 14, 14, 14, 14, 1	in 18 idities Megetie Las 1,00 70 70 70 70 70 70 70 70 70 70 70 70 7	1141 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	38.	M 5

Patient Facing Technology (TeleHealth)

- Outpatient encounters transitioned from in person to video visits
- Multi-provider capable
- Use expanded to inpatient



© 2020 Epic Systems Corporation. Used with permission.

Rapid Expansion of TeleHealth Capabilities



TeleHealth eConsent

Non- Patient S	ignature Information
Patient signing for	Yes
selfr	No - Signed by other
Relationship to Pat	lent
Telehealth - Video	/isit \$
Signed by (if other	than Patient)
Signature Not Appli	cable
Date:	
	•
Reason, if not sign	ed by patient:
D * 5 0 0	.? + Insert SmartText 🖷 More -
Telemedicine Vid	eo Visit - Telehealth Consent by Patient.
listed below.	as witnessed by the healthcare provider

^{© 2020} Epic Systems Corporation. Used with permission.

EHR-Integrated Secure Messaging

Chat Securely in Hyperspace

Chat securely with your colleagues from your computer. Please refer to UCSD Health Medical Center Policies (MCP's) on the appropriate use of Epic Secure Chat.



Artificial Intelligence in Diagnostic Radiology



Challenges and Limitations

- Usual process out the window
- Bandwidth of Information Services department put to the test
- Approval from multiple stakeholders
 - Daily engagement huddles
- Focus on non-COVID medical care
 - Usual projects put on hold

Next Steps for Health IT in COVID-19

- Data sharing across health systems, regions, states, and countries
- TeleHealth finding the appropriate balance
- 3T Stategy Testing, tracing, and treatment¹



1. San Diego Health & Human Service Agency (HHSA) Director Nick Macchione

TeleHealth vs In-Person



Health IT and Contact Tracing

Am J Infect Control. 2008 Apr; 36(3): S37–S46. Published online 2008 Mar 26. doi: <u>10.1016/j.ajic.2008.01.002</u> PMCID: PMC7115272 PMID: <u>18374211</u>

Opportunities and challenges in utilizing electronic health records for infection surveillance, prevention, and control

Ashish Atreja, MD, MPH,^{a,*} Steven M. Gordon, MD,^a Daniel A. Pollock, MD,^b Russell N. Olmsted, MPH, CIC,^c Patrick J. Brennan, MD,^d and Healthcare Infection Control Practices Advisory Committee



Health IT and Contact Tracing

Viewpoint

March 3, 2020

Response to COVID-19 in Taiwan Big Data Analytics, New Technology, and Proactive Testing

C. Jason Wang, MD, PhD12; Chun Y. Ng, MBA, MPH2; Robert H. Brook, MD, ScD3,4

> Author Affiliations | Article Information JAMA. 2020;323(14):1341-1342. doi:10.1001/jama.2020.3151



E ¥ = 2



- Case identification and remote monitoring
- Government database w/ access granted to hospitals, clinics, and pharmacies
- Centralized versus decentralized tracing through use of smart phones



Key Points/Lessons Learned

- COVID-19 required unprecedented response
- The EHR can be your friend, use it well
- Overview of specific EHR-based tools
- Strong relationship between clinicians and analysts is the most important aspect to successful integration of EHR-based tools



Thank you!

Chris Longhurst, MD, MS clonghurst@ucsd.edu @calonghurst

UC San Diego Health